PURPOSE: To compare mortality among patients with selected autoimmune diseases treated with anti-tumor necrosis factor alpha (TNF-α) agents with similar patients treated with non-biologic therapies. METHODS: Cohort study set within several large health care programs, 1998-2007. Autoimmune disease patients were identified using diagnoses from computerized healthcare data. Use of anti-TNF-α agents and comparison of non-biologic therapies were identified from pharmacy data, and mortality was identified from vital records and other sources. We compared new users of anti-TNF-α agents to new users of non-biologic therapies using propensity scores and Cox proportional hazards analysis to adjust for baseline differences. We also made head-to-head comparisons among anti-TNF-α agents. RESULTS: Among the 46 424 persons included in the analysis, 2924 (6.3%) had died by the end of follow-up, including 1754 (6.1%) of the 28 941 with a dispensing of anti-TNF-α agent and 1170 (6.7%) of the 17 483 who used non-biologic treatment alone. Compared to use of non-biologic therapies, use of anti-TNF-α therapy was not associated with an increased mortality in patients with rheumatoid arthritis (adjusted hazard ratio [aHR] 0.93 with 95% confidence intervals (CI) 0.85-1.03); psoriasis, psoriatic arthritis, or ankylosing spondylitis (combined aHR 0.81 with CI 0.61-1.06; or inflammatory bowel disease (aHR 1.12 with CI 0.85-1.46). Mortality rates did not differ to an important degree between patients treated with etanercept, adalimumab, or infliximab. CONCLUSION: Anti-TNF-α therapy was not associated with increased mortality among patients with autoimmune diseases.
PURPOSE: To compare mortality among patients with selected autoimmune diseases treated with anti-tumor necrosis factor alpha (TNF-α) agents with similar patients treated with non-biologic therapies. METHODS: Cohort study set within several large health care programs, 1998-2007. Autoimmune diseasepatients were identified using diagnoses from computerized healthcare data. Use of anti-TNF-α agents and comparison of non-biologic therapies were identified from pharmacy data, and mortality was identified from vital records and other sources. We compared new users of anti-TNF-α agents to new users of non-biologic therapies using propensity scores and Cox proportional hazards analysis to adjust for baseline differences. We also made head-to-head comparisons among anti-TNF-α agents. RESULTS: Among the 46 424 persons included in the analysis, 2924 (6.3%) had died by the end of follow-up, including 1754 (6.1%) of the 28 941 with a dispensing of anti-TNF-α agent and 1170 (6.7%) of the 17 483 who used non-biologic treatment alone. Compared to use of non-biologic therapies, use of anti-TNF-α therapy was not associated with an increased mortality in patients with rheumatoid arthritis (adjusted hazard ratio [aHR] 0.93 with 95% confidence intervals (CI) 0.85-1.03); psoriasis, psoriatic arthritis, or ankylosing spondylitis (combined aHR 0.81 with CI 0.61-1.06; or inflammatory bowel disease (aHR 1.12 with CI 0.85-1.46). Mortality rates did not differ to an important degree between patients treated with etanercept, adalimumab, or infliximab. CONCLUSION: Anti-TNF-α therapy was not associated with increased mortality among patients with autoimmune diseases.
Authors: Til Stürmer; Sebastian Schneeweiss; M Alan Brookhart; Kenneth J Rothman; Jerry Avorn; Robert J Glynn Journal: Am J Epidemiol Date: 2005-05-01 Impact factor: 4.897
Authors: Lennart T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek Journal: J Rheumatol Date: 2005-07 Impact factor: 4.666
Authors: Sarah M Lyon; Nicole M Benson; Colin R Cooke; Theodore J Iwashyna; Sarah J Ratcliffe; Jeremy M Kahn Journal: Am J Respir Crit Care Med Date: 2011-10-01 Impact factor: 21.405
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Lisa J Herrinton; Jeffrey R Curtis; Lang Chen; Liyan Liu; Elizabeth Delzell; James D Lewis; Daniel H Solomon; Marie R Griffin; Rita Ouellet-Hellstom; Timothy Beukelman; Carlos G Grijalva; Kevin Haynes; Bindee Kuriya; Joyce Lii; Ed Mitchel; Nivedita Patkar; Jeremy Rassen; Kevin L Winthrop; Parivash Nourjah; Kenneth G Saag Journal: Pharmacoepidemiol Drug Saf Date: 2011-09-15 Impact factor: 2.890
Authors: Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel Journal: Arthritis Rheum Date: 2007-11
Authors: Lisa J Herrinton; Leslie R Harrold; Liyan Liu; Marsha A Raebel; Ananse' Taharka; Kevin L Winthrop; Daniel H Solomon; Jeffrey R Curtis; James D Lewis; Kenneth G Saag Journal: Pharmacoepidemiol Drug Saf Date: 2013-01-29 Impact factor: 2.890
Authors: Maria de Fátima Santos Paim de Oliveira; Bruno de Oliveira Rocha; Gleison Vieira Duarte Journal: An Bras Dermatol Date: 2015 Jan-Feb Impact factor: 1.896